Monday, 25 Mar 2019

You are here

BMS Tyk 2 Inhibitor Benefits Psoriasis

The NEJM reports that an oral selecive Tyrosine kinase 2 (TYK2) inhibitor of TYK2 was shown to be superior to placebo in a 12 week trial in patients with active psoriasis.

In a 12 week, phase 2, double-blind trial, BMS-986165 (TYK2 inhibitor) or placebo was given to 267 patients with active moderate-to-severe psoriasis, who previously failed to respond to other targeted cytokine inhibitors.  Patients received wither 3 mg every other day, 3 mg daily, 3 mg twice daily, 6 mg twice daily, or 12 mg daily or to receive placebo. The primary end point was a 75% or greater reduction from baseline in the Psoriasis Area and Severity Index (PASI75) score at week 12.

At week 12, the PASI 75 response rates were:

  • PBO: 7% (3 of 45 patients)
  • 3 mg of BMS-986165 qod;  9% (4 of 44 patients) (P=0.49 vs. placebo)
  • 3 mg qd: 39% (17 of 44 patients) (P<0.001 vs. placebo)
  • 3 mg bid:  69% (31 of 45 patients) (P<0.001 vs. placebo)
  • 6 mg bid: 67% (30 of 45 patients) (P<0.001 vs. placebo)
  • 12 mg qd: 75% (33 of 44 patients) (P<0.001 vs. placebo).

Discontinuation rates were low, generally about 2% (ranging from 2-7%) and there were 3 serious adverse events in patients receiving the active drug, as well as one case of malignant melanoma 96 days after the start of treatment.

Targeted inhibition of TYK2 with the oral agent BMS-986165 at doses of 3 mg daily and higher resulted in significant clearing of psoriasis.

(Funded by Bristol-Myers Squibb; ClinicalTrials.gov number, NCT02931838.)

Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

Biologic Agents have Equal Efficacy in Enthesitis and Dactylitis

A systematic review has shown that TNF inhibitors (TNFi) are equaled in efficacy by other biologic agents (ustekinumab, secukinumab, and ixekizumab) in psoriatic arthritis (PsA) patients with in dactylitis and enthesitis.

The literature review analyzed datafrom randomized controlled trials (RCTs) with TNFi (infliximab, golimumab, adalimumab), antiinterleukin- 12/23 (ustekinumab) and anti-interleukin-17 (secukinumab, ixekizumab).

Dual IL-17 Inhibitor in Psoriasis Succeeds

Patients with moderate-to-severe plaque psoriasis attained durable complete and near-complete responses for more than a year with a dual inhibitor of interleukin (IL)-17, data from a randomized trial showed. 

AAD/NPF Guidelines on Biologic Use in Psoriasis

Menter and colleagues from the American Academy of Dermatology (AAD) and National Psoriasis Foundation (NPF) have published their expert consensus guidelines for the use of biologics in psoriasis.

Dermatology Guidelines for Psoriatic Comorbidities

The JAAD has published joint guidelines from the American Academy of Dermatology (AAD) and National Psoriasis Foundation (NPF) on the approach, management and dermatolgist roles for select comorbid conditions. 

Early TNF inhibition in Early Psoriatic Arthritis

A small, double-blind, randomised, placebo-controlled trial in early psoriatic arthritis (PsA) has shown that first-line use of golimumab and methotrexate (MTX) is superior to MTX alone in inducing remission in PsA.